• Kon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer
  • Lisa Ooi, PhD, appointed Chief Operating Officer

SAN FRANCISCO and SINGAPORE, July 29, 2024 — Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, announced the appointments of Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.

Dr. Kwek, formerly Senior Vice President of Clinical Development, joined Hummingbird Bioscience in 2022. He brings over 20 years of experience from Akeso Biopharma, Eli Lilly, and IQVIA, as well as clinical practice. Dr. Kwek will lead the company’s clinical development from Singapore.

“Our clinical-stage assets, HMBD-001 and HMBD-002, are in clinical trials in the U.S., Australia, and Singapore. We are now accelerating the development of these therapies by expanding our trial sites to more countries and focusing on selected tumor types, which we believe may benefit from these therapies. I look forward to the next milestones in our clinical programs and progressing more of our pre-clinical pipeline to the clinic,” said Dr. Kwek.

Dr. Ooi, formerly Senior Vice President of Strategy, joined the company in 2022. She brings over 20 years of experience from Singapore’s government agencies and biopharma industry, including the Economic Development Board, Agency for Science, Technology and Research (A*STAR), ASLAN Pharmaceuticals, and Bayer.

“I am delighted to lead the team’s strategy towards its next phase of growth, building upon our strong scientific capabilities and commitment to deeply understanding tumor biology. With our proprietary antibody and dual-payload ADC platform technologies, I look forward to what we will achieve in the coming year,” said Dr. Ooi.

About Hummingbird Bioscience

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

For more information, please visit , and follow Hummingbird Bioscience on , , and .

CONTACT: Hummingbird Bioscience Media Contact:

Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580

Hummingbird Bioscience Investor Contact:

investors@hummingbirdbio.com